Related Experiment Videos
A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey
E Bezard1, C Imbert, X Deloire
1Laboratoire de Neurophysiologie, CNRS UMR 5543, Université de Bordeaux II, France. erwan.bezard@umr5543.u-bordeaux2.fr
Abstract:
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) has been shown to induce parkinsonism both in man and non-human primates. Several models have now been developed, but acute MPTP administration does not consistently reproduce all the clinical features of the disease. To mirror the slow evolution observed in human pathology, a chronic model of intoxication is necessary. The present study describes a chronic MPTP protocol in the monkey. Six monkeys received daily injections of MPTP (0.2 mg/kg i.v.) until they reached a score over 8 on the clinical rating scale (15.5 days +/- 1.1). Full parkinsonism was first obtained on the 22nd day. Levodopa testing (20 mg/kg per os) alleviated motor abnormalities (51%), proving the parkinsonian nature of these disturbances. Histological lesions reproduced those observed in Parkinson's disease with a decrease in tyrosine hydroxylase immunoreactivity of 90%. This model so could be of great interest for the study of the dynamic physiopathological changes which occur in Parkinson's disease and consequently for research on new neuroprotective therapies.
Insights
A chronic MPTP model in monkeys successfully replicated Parkinson's disease features, including motor deficits and neurodegeneration. This primate model offers a valuable tool for studying Parkinson's disease progression and testing new neuroprotective therapies.
Area of Science:
- Neuroscience
- Primate Models
- Parkinson's Disease Research
Background:
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induces parkinsonism in humans and non-human primates.
- Acute MPTP models do not fully capture the progressive nature of Parkinson's disease.
Purpose of the Study:
- To develop and validate a chronic MPTP intoxication protocol in monkeys.
- To establish a reliable primate model that mirrors the slow evolution of human Parkinson's disease.
Main Methods:
- Six monkeys received daily intravenous injections of MPTP (0.2 mg/kg).
- Clinical rating scales were used to monitor parkinsonism development.
- Levodopa administration and histological analysis (tyrosine hydroxylase immunoreactivity) were performed.
Main Results:
- Full parkinsonism was achieved by day 22.
- Levodopa treatment alleviated motor abnormalities by 51%, confirming the parkinsonian nature of the symptoms.
- Histological examination revealed a 90% decrease in tyrosine hydroxylase immunoreactivity, consistent with Parkinson's disease.
Conclusions:
- A chronic MPTP protocol in monkeys provides a robust model for Parkinson's disease.
- This model is suitable for investigating the dynamic physiopathological changes in Parkinson's disease.
- The model can facilitate research into novel neuroprotective therapies for Parkinson's disease.